VERU News and Press, Veru Inc. From 12/11/23

Lanvin Group Holdings Limited (LANV) is expected to report for quarter end 2023-09-30 Sonnet BioTherapeutics Holdings Inc. (SONN) is expected to report for Q4 2023 Shionogi & Co. Ltd. ADR (SGIOY) is expected to report for Q2 2024 Gelesis Holdings, Inc. (GLSHQ) is expected to repor...

JanOne Inc. (JAN) is expected to report for Q4 2023 Staffing 360 Solutions Inc. (STAF) is expected to report $-0.31 for Q3 2023 American Virtual Cloud Technologies Inc. (AVCTQ) is expected to report for quarter end 2023-09-30 Quotient Limited (QTNTQ) is expected to report for quarter ...

Veru Inc. (VERU) is expected to report $-0.2 for Q4 2023

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Veru Inc. (NasdaqCM: VERU). Following the onset of the COVID-19 pandemic, the Company pursued...

2023-10-04 10:05:55 ET More on Veru Veru Inc. (VERU) Q2 2023 Earnings Call Transcript Stay Away From Veru Until 2024 Seeking Alpha’s Quant Rating on Veru Historical earnings data for Veru Financial information for Veru For further detai...

-- In 5 clinical studies involving 968 older men and postmenopausal women with and without muscle wasting, enobosarm has demonstrated the ability to decrease fat mass, increase muscle mass, and improve muscle strength and physical function -- -- Weight-loss drugs like Ozempic, Weg...

--Reached agreement with FDA on single Phase 3 clinical trial design to expand treatment population to include all hospitalized adult patients with any type of virus induced ARDS including the “tripledemic viruses”: Influenza, RSV, and SARS-CoV-2-- -- Based on high morta...

MIAMI, FL, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for metastatic breast cancer and for viral induced acute respiratory distress syndrome (ARDS), today announced that Mitchell Steiner, M.D.,...

-- Overall response rates of 12.5% are observed in the enobosarm group in a heavily pretreated population versus no responses in the standard of care active control arm. On average, enobosarm or active control was given in the 4 th line treatment in the metastatic setting whic...

MIAMI, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for metastatic breast cancer and for viral induced acute respiratory distress syndrome (ARDS), today announced that Mitchell Steiner, M.D., Chai...